Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients
Abouzeid, T., El-Ashwah, S., Aref, S., Farag, N., Farag, R. (2022). Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients. EKB Journal Management System, 87(1), 2253-2258. doi: 10.21608/ejhm.2022.234292
Tarek Elsayed Abouzeid; Shaimaa El-Ashwah; Salah Aref; Nora A. Farag; Rania K. Farag. "Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients". EKB Journal Management System, 87, 1, 2022, 2253-2258. doi: 10.21608/ejhm.2022.234292
Abouzeid, T., El-Ashwah, S., Aref, S., Farag, N., Farag, R. (2022). 'Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients', EKB Journal Management System, 87(1), pp. 2253-2258. doi: 10.21608/ejhm.2022.234292
Abouzeid, T., El-Ashwah, S., Aref, S., Farag, N., Farag, R. Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients. EKB Journal Management System, 2022; 87(1): 2253-2258. doi: 10.21608/ejhm.2022.234292

Evaluating The Risk of Thrombosis and Its Relation to JAKII Mutation in Egyptian Myeloproliferative Neoplasm Patients

The Egyptian Journal of Hospital Medicine
Article 207, Volume 87, Issue 1, April 2022, Page 2253-2258  XML PDF (416.84 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.234292
View on SCiNiTO View on SCiNiTO
Authors
Tarek Elsayed Abouzeid email orcid ; Shaimaa El-Ashwah; Salah Aref; Nora A. Farag; Rania K. Farag
mansoura oncology center elgomheyia street
Abstract
Background:Vascular thrombosis represents a common manifestation, and complication in patient with myeloproliferative neoplasm (MPN). It is also associated with higher risk of morbidity and mortality. The acquired point mutation in Janus Associated Kinase II (JAKIIV617F) in these disorders is associated with higher incidence of thrombosis compared to patient devoid of this mutation.
Objective: This study aimed to evaluate the incidence of thrombosis, and its relation to JAK II (V617F) mutation among Egyptian MPN patients
Patients and Method: In this, study 102 patients (49 males and 53 females) at the Outpatient Clinic of Mansoura Oncology Center has been evaluated for the presence and type of thrombosis. In addition, its relation to JAKII mutation.
Results: From the 102-studied patients, 47 (46.15%) had Polycythemia Vera (PV), 27(26.5%) had essential thrombocytosis (ET), 22 (21.6%) had myelofibrosis (MF), and 6 (5.9%) patients had unclassified MPN. Vascular thrombosis has been observed in 34 (33.3%) patients, 28 (27.5%) of them at the time of diagnosis, 6 (5.9%) patients at follow up and 4 (3.9%) were having recurrent thrombosis. According to the pattern of thrombosis, 16 patients had arterial thrombosis, 14 had venous, and 4 patients had combined arterio-venous thrombosis. The association of of JAK II V617F mutation and thrombosis were statistically significant (P = 0.0003).
Conclusion: The presence of JAKII V617F mutation is associated with higher incidence of vascular thrombosis in MPN patients compared to those without this mutation.
 
Keywords
MPN; JAKII; Thrombosis
Statistics
Article View: 141
PDF Download: 236